(Q37875051)

24 August 2017

1 reference

title

Health technology funding decision-making processes around the world: the same, yet different (English)

1 reference

24 August 2017

1 reference

4

Christopher McCabe

1 reference

24 August 2017

Tania Stafinski

1

1 reference

24 August 2017

Devidas Menon

series ordinal

2

1 reference

24 August 2017

Donald J Philippon

series ordinal

3

1 reference

24 August 2017

publication date

1 June 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

29

1 reference

24 August 2017

issue

6

1 reference

24 August 2017

page(s)

475-495

1 reference

Health care priority setting: principles, practice and challenges

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11586420-000000000-00000

Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586420-000000000-00000

How hospitals confront new technology

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586420-000000000-00000

Limits to health care: fair procedures, democratic deliberation, and the legitimacy problem for insurers.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586420-000000000-00000

Centralized drug review processes in Australia, Canada, New Zealand, and the United kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586420-000000000-00000

Comparative effectiveness research and evidence-based health policy: experience from four countries

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586420-000000000-00000

Austria: history of health technology assessment during the past 20 years

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586420-000000000-00000

Belgian methodological guidelines for pharmacoeconomic evaluations: toward standardization of drug reimbursement requests

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586420-000000000-00000

Introduction of emerging medical devices on the market: a new procedure in Belgium

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586420-000000000-00000

The Danish health care system: evolution--not revolution--in a decentralized system

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586420-000000000-00000

Pharmaceutical pricing and reimbursement reforms in Greece

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586420-000000000-00000

Evidence-based decision-making on medical technologies in China, Japan, and Singapore

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586420-000000000-00000

Prioritizing health-care funding

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586420-000000000-00000

Reimbursement systems, organisational forms and patient selection: evidence from day surgery in Norway

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586420-000000000-00000

Priority setting for high cost medications (HCMs) in public hospitals in Australia: a case study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586420-000000000-00000

Role of health technology assessment in shaping the benefits package in The Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586420-000000000-00000

Impact analysis of the discontinuation of reimbursement: the case of oral contraceptives

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586420-000000000-00000

Conditional reimbursement within the Dutch drug policy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586420-000000000-00000

Criteria for determining a basic health services package. Recent developments in The Netherlands.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586420-000000000-00000

Linking evidence from health technology assessments to policy and decision making: the Alberta model

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586420-000000000-00000

Establishing a comprehensive continuum from an evidentiary base to policy development for health technologies: the Ontario experience

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586420-000000000-00000

Overview of health technology assessment in France

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586420-000000000-00000

Reform of prescription drug reimbursement and pricing in the German social health insurance market: a comparison of three scenarios.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586420-000000000-00000

Pharmacoeconomic evaluation in Ireland: a review of the process

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586420-000000000-00000

Recent developments in pricing and reimbursement of medicines in Ireland

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586420-000000000-00000

A case study of ex ante, value-based price and reimbursement decision-making: TLV and rimonabant in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586420-000000000-00000

Implementing accountability for reasonableness--the case of pharmaceutical reimbursement in Sweden.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586420-000000000-00000

Reimbursement and clinical guidance for pharmaceuticals in Sweden: do health-economic evaluations support decision making?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586420-000000000-00000

Informing disinvestment through cost-effectiveness modelling: is lack of data a surmountable barrier?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586420-000000000-00000

Public funding of new cancer drugs: Is NICE getting nastier?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586420-000000000-00000

NICE and judicial review: enforcing 'accountability for reasonableness' through the courts?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586420-000000000-00000

Cost-effectiveness analysis and formulary decision making in England: findings from research

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586420-000000000-00000

Has NICE been nice to cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586420-000000000-00000

Continuing the multiple sclerosis risk sharing scheme is unjustified.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586420-000000000-00000

Medicare's national coverage decisions, 1999-2003: quality of evidence and review times

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586420-000000000-00000

The National Oncologic PET Registry: lessons learned for coverage with evidence development

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586420-000000000-00000

Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586420-000000000-00000

National Institute for Clinical Excellence and its value judgments

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586420-000000000-00000

Prioritisation by physicians in the Netherlands—The growth hormone example in drug reimbursement decisions

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586420-000000000-00000

Regulating the Dutch pharmaceutical market: improving efficiency or controlling costs?

21 January 2018

1 reference

12 December 2020

Managing public payment for high-cost, high-benefit treatment: enzyme replacement therapy for Gaucher's disease in Ontario

1 reference

12 December 2020

Comparative effectiveness review within the U.K.'s National Institute for Health and Clinical Excellence.

1 reference

12 December 2020

Evidence-based decision-making within Australia's pharmaceutical benefits scheme

1 reference

12 December 2020

Site-ation pearl growing: methods and librarianship history and theory.

1 reference

12 December 2020

How good is good enough? Standards in policy decisions to cover new health technologies

1 reference

12 December 2020

Access to drugs for cancer: Does where you live matter?

1 reference

12 December 2020

National Authority for Health: France.

1 reference

12 December 2020

Going against the flow: the impact of PHARMAC not funding COX-2 inhibitors for chronic arthritis

1 reference

12 December 2020

The "health benefit basket" in the Netherlands

1 reference

12 December 2020

Paying for costly pharmaceuticals: regulation of new drugs in Australia, England and New Zealand

1 reference

12 December 2020

Antibiotics in Dutch general practice: nationwide electronic GP database and national reimbursement rates

1 reference

12 December 2020

How to anticipate the assessment of the public health benefit of new medicines?

1 reference

12 December 2020

Health technology assessment in Finland

1 reference

12 December 2020

Medicare and medical technology--the growing demand for relevant outcomes

1 reference

12 December 2020

Priority-setting and rationing in German health care

1 reference

12 December 2020

Institute for Quality and Efficiency in Health Care: Germany.

1 reference

12 December 2020

PHARMAC not funding some treatments for rare, life-threatening diseases: bosentan as an example

1 reference

12 December 2020

[If you are young you get it, but if you are old you are left out. The significance of age for choice of treatment and priorities in cancer care]

1 reference

12 December 2020

Health technology assessment in Australia: challenges ahead

1 reference

12 December 2020

Clinical excellence and the NICEties of value-based priority setting

1 reference

12 December 2020

Pricing and reimbursement of pharmaceuticals in Italy

1 reference

12 December 2020

"Prioritization": rationing health care in New Zealand

1 reference

12 December 2020

The biggest bang for the buck or bigger bucks for the bang: the fallacy of the cost-effectiveness threshold

1 reference

12 December 2020

Priority-setting decisions for new cancer drugs: a qualitative case study

1 reference

12 December 2020

Incremental cost-effectiveness ratios (ICERs): the silence of the lambda

1 reference

12 December 2020

10.2165/11586420-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

24 August 2017

1031519303

0 references

1 reference